What is Quris Technologies?
Founded in 2020 and headquartered in Tel-Aviv, Israel, Quris Technologies has developed a sophisticated Bio-AI Clinical Prediction Platform. This innovative technology aims to revolutionize the pharmaceutical industry by enhancing the predictability of which drug candidates will demonstrate safety and efficacy in human trials. By leveraging artificial intelligence, Quris seeks to reduce the high failure rates and costs associated with traditional drug development, thereby accelerating the path to market for new therapeutics.
How much funding has Quris Technologies raised?
Quris Technologies has raised a total of $9M across 1 funding round:
Angel/Seed
$9M
Angel/Seed (2022): $9M with participation from iAngels, Richter Group, Glenrock Capital, Softbank Vision Fund, and Welltech Ventures
Key Investors in Quris Technologies
iAngels
iAngels is an Israeli venture capital firm and investment platform that provides accredited investors with access to tech startups. They focus on curated investment opportunities and have a significant presence in the Israeli tech ecosystem.
Softbank Vision Fund
SoftBank Vision Fund is a global investment fund that supports technology-focused companies, particularly in the AI sector, providing capital and ecosystem resources to foster market leadership and innovation.
Welltech Ventures
WellTech Ventures is a venture capital fund specializing in wellness technology, investing in startups that aim to improve health and wellness through innovative solutions in areas like personalized medicine and mental health.
What's next for Quris Technologies?
The substantial backing Quris Technologies has received, particularly the recent major strategic investment, positions the company for accelerated growth and market expansion. This capital is likely to be deployed towards further enhancing its Bio-AI platform, expanding its research and development capabilities, and forging strategic partnerships within the pharmaceutical and biotechnology sectors. Quris's focus on de-risking drug development through predictive AI aligns with the industry's increasing demand for efficiency and innovation, suggesting a trajectory towards becoming a key player in the future of pharmaceutical R&D.
See full Quris Technologies company page
